Structure Therapeutics
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Structure Therapeutics (GPCR) | 1.15B | -4.14 | 0.95 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 61.7% below Morningstar's fair value estimate.
Fair value
Structure Therapeutics Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 23% discount to our quantitative fair value estimate of $26.08 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 1.1 falls in the bottom 10% compared with global peers. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be undervalued.
On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, sits in the top 30% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Structure Therapeutics discussion 0 comments